The CHOICE study performed by Jaar et al.11 studied 1041 patients on HD and PD from 81 dialysis clinics in the United States. They were prospectively studied for up to 7 years after commencement. Data were gathered on coexisting diseases and disease severity along with age, sex, ethnicity, serum albumin, Hb, C-reactive protein, residual urine output and BMI. After adjustment, the risk of death did not differ between HD and PD patients undergoing treatment for the first 12 months. However, after the second year, the mortality risk was significantly higher in the PD group. This study did not find an increased risk of death with

PD for diabetic or elderly patients; however, there was a somewhat greater risk of death for some groups on Selleckchem DMXAA PD if the patient had a history of CVD (not statistically significant in all subgroups). Limitations: Measured dialysis adequacy was not available for all patients to make a comparison between modalities and possibly associate with survival. A selection bias could influence results due to the observational nature of this study. This study allowed for modality switching without analysis of the reasons and the survival outcome. Registry data analysis from

the USA, the Netherlands, Canada, Italy and Denmark is included here. Canadian Organ Replacement Register data analysis by Fenton et al.5 studied 11 970 patients with stage 5 kidney disease commencing PD98059 datasheet treatment in Canada from 1990 until 1994 with up to 5 years of follow up. Deaths were allocated to the treatment the patient was

receiving at the time of their death. Data were adjusted for age, primary renal disease, centre size and predialysis comorbidities. Lck Results indicated that the mortality risk for patients commencing treatment with PD was 73% that of those commencing with HD when adjusting for various prognostic factors; however, this became less pronounced when various subgroups were teased out (especially for those with diabetes and over the age of 65 years). The mortality rate for those on PD tended to increase over time while the HD survival was represented by a U shape. Limitations: This study did not adjust registry data for the impact of dialysis adequacy, nutritional status, patient compliance, comorbidity severity and the effect of late referral on patient mortality. United States Renal Data System (USRDS) registry data analysis. This registry data study by Vonesh and Moran3 extracted mortality data on nearly 204 000 patients from the USRDS for incident and prevalent patients over a 7-year period from 1987 to 1993. The results showed significant variations in mortality rates according to specific cohorts studied such as age, diabetes and gender. Importantly, there were no statistically significant differences in the adjusted death rates among non-diabetic PD and HD patients across age, gender or race.